Universität zu Köln

Westphalen, C. Benedikt, Heinemann, Volker, Tessen, Hans Werner, Groschek, Matthias, Hoeffkes, Heinz-Gert, Marschner, Norbert, Schulze, Mathias, Beringer, Andreas and Waldschmidt, Dirk (2020). Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial. Z. Gastroent., 58 (4). S. 332 - 341. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-7803

Full text not available from this repository.

Abstract

Metastatic pancreatic cancer has the worst prognosis of all cancers. With nab-Paclitaxel/gemcitabine, FOLFIRINOX, and gemcitabine/erlotinib, several treatment options are available which improve the patient's overall survival. Especially for patients who develop rash under erlotinib treatment can benefit from gemcitabine/erlotinib combination therapy. This non-interventional study (NIS ML21284) investigated the effectiveness and tolerability of gemcitabine/erlotinib therapy in the treatment routine of metastatic pancreatic cancer, in particular, in the context of the occurrence of a rash. Between 2007 and 2010, the treatment data of 433 patients in 98 centres were documented. All parameters recorded were assessed descriptively. Treatment with gemcitabine/erlotinib resulted in both a significant increased median overall survival of the patient subgroup with rash grade >= 1 (9.90; 95 % confidence interval [CI], 8.19 to 11.05 vs. 6.48 months; 95 % CI, 5.66 to 7.40, p = 0.0010) and median progression-free survival (5.43, 95 % CI, 4.90 to 6.12 vs. 3.98 months, 95 % CI, 3.52 to 5.03, p = 0.0131). The overall response rate of patients treated with gemcitabine/erlotinib, who had developed rash grade >= 1, was 5.9 % higher compared to patients without rash (31.7 % vs. 25.8 %). In conclusion, these results from the daily treatment routine of metastatic pancreatic cancer underline the importance of combined gemcitabine/erlotinib therapy for a subgroup of patients who develop a rash in the course of erlotinib treatment.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Westphalen, C. Benedikt UNSPECIFIED UNSPECIFIED UNSPECIFIED Heinemann, Volker UNSPECIFIED UNSPECIFIED UNSPECIFIED Tessen, Hans Werner UNSPECIFIED UNSPECIFIED UNSPECIFIED Groschek, Matthias UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoeffkes, Heinz-Gert UNSPECIFIED UNSPECIFIED UNSPECIFIED Marschner, Norbert UNSPECIFIED UNSPECIFIED UNSPECIFIED Schulze, Mathias UNSPECIFIED UNSPECIFIED UNSPECIFIED Beringer, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Waldschmidt, Dirk UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-338394
DOI:	10.1055/a-1071-8177
Journal or Publication Title:	Z. Gastroent.
Volume:	58
Number:	4
Page Range:	S. 332 - 341
Date:	2020
Publisher:	GEORG THIEME VERLAG KG
Place of Publication:	STUTTGART
ISSN:	1439-7803
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PHASE-III TRIAL; GROWTH-FACTOR RECEPTOR; SURVIVAL; COMBINATION; RASH; FLUOROURACIL; CHEMOTHERAPY; FOLFIRINOX; CISPLATIN; EFFICACY Multiple languages Gastroenterology & Hepatology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/33839